April 11, 2014/Cancer/Radiation Oncology

Hyperthermia Improves Response Rates in Recurrent Cancers

Heating tumor sensitizes cancer stem cells to radiation effects

hyperthermia-690×380

A large number of clinical studies show that treatment with hyperthermia in combination with radiation leads to a better response than radiation alone in a variety of cancers, particularly for superficial cancers. Well controlled studies show that the combination treatment can increase complete response rates in patients with recurrent breast cancer compared with radiation alone, particularly for those patients who have had prior radiation.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Yet despite these benefits, the treatment is not widely available. Cleveland Clinic’s Taussig Cancer Institute is the only cancer program in Ohio and one of the few in the United States to offer hyperthermia.

Sensitizing cancer stem cells

Hyperthermia is a noninvasive method of increasing tumor temperature, which makes it more sensitive to radiation effects. “Our group has shown that the addition of hyperthermia to radiation can sensitize cancer stem cells — which are fairly resistant to radiation and to chemotherapy alone — to subsequent radiation treatment,” says Jennifer Yu, MD, PhD, radiation oncologist at Taussig Cancer Institute, and a cancer researcher in Stem Cell Biology and Regenerative Medicine at Lerner Research Institute.

“Hyperthermia makes radiation much more efficacious,” Dr. Yu says.” The combination of hyperthermia and radiation in particular is a great treatment for patients who have failed prior chemotherapy and failed prior radiation therapy.”

Taussig Cancer Institute houses a hyperthermia unit that is primarily used for treating superficial cancers. Within the past 2 years, more than 25 patients have received this treatment. Most patients seen have recurrent breast cancers, and some patients have unresectable melanoma and recurrent vulvar cancers that previously had been irradiated. “We have the capacity to treat deeper tumors as well, such as advanced cervical cancer,” Dr. Yu says.

Advertisement

Hyperthermia helps address the limitations of repeat radiation for many patients by effectively increasing the radiation dose without substantially increasing side effects. “With the addition of hyperthermia, we are able to use lower radiation doses and yet have comparable results that are seen with higher doses,” says Dr. Yu. She explains that hyperthermia effectively increases the amount of radiation a patient receives by about 50 percent.

Proven protocols

Hyperthermia is done prior to each radiation treatment. For recurrent breast cancer, treatment requires about 60 minutes of hyperthermia, followed by radiation. During the treatment, a heated water bolus is placed on the tumor plus a small area around it. A microwave unit on top heats the treatment area to 109 to 110 degrees Fahrenheit.

Physicians use thermistors to measure temperature in real time, to ensure the tumor is receiving adequate heating, not over- or under heating. “The hyperthermia we use involves mild but effective temperatures,” says Dr. Yu. “It is not so high that the tumor is destroyed, such as with thermal ablation.”

After the procedure, some patients may feel mild to moderate pain; others just feel warm. Most patients do not require pain medication. Many patients are sufficiently relaxed that they fall asleep during the hyperthermia treatment.

Advertisement

Well-tolerated procedure

Patients typically receive hyperthermia/radiation treatment twice a week, but it may vary due to the radiation protocol prescribed. Each hyperthermia session must be accompanied by radiation or, in some cases, chemotherapy. Hyperthermia is generally well-tolerated. A minority of patients develop skin blistering or ulceration that typically heals with conservative measures.

Most patients referred to Taussig Cancer Institute’s hyperthermia unit are sent by medical oncologists who have tried multiple types of chemotherapy, or radiation oncologists who are aware of the benefits of hyperthermia and radiation.

Related Articles

22-CNR-3127708-CQD-Hero2-650×450-credits
November 22, 2023/Cancer/Radiation Oncology
A Germline Biomarker Offers Insight Into Treatment Selection for Men With Prostate Cancer

Correlation found between the biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

23-CNR-4164208 ASTRO 2023 graphic CQD
September 21, 2023/Cancer/Radiation Oncology
Top 10 Presentations You Don’t Want to Miss at ASTRO 2023

Highlighting top abstracts for the annual radiation oncology conference

23-CNR-3964459-CQD-Hero-650×450 SBRT
New Study Highlights Potential Benefits of Ultrasound-Guided Prostate SBRT

Transperineal ultrasound a viable, non-invasive option for monitoring intra-fractional prostate motion

ASTRO 2022 abstracts
November 4, 2022/Cancer/Radiation Oncology
Top Research from ASTRO 2022

Key abstracts highlight advances in treating locally advanced and refractory disease

radiation therapy
October 14, 2022/Cancer/Radiation Oncology
Radiation Oncology-Biology Integration Network (ROBIN) Explores Precision Medicine

Multidisciplinary team to examine radiation therapy combined with immunotherapy

21-CNR-2572058-CQD-Hero-650×450-1
March 17, 2022/Cancer/Radiation Oncology
Aggressive Daily Radiation in Breast Cancer Survivor with Angiosarcoma: A Case Study

Preoperative treatment ensures successful surgical resection

Squamous Cell carcinoma under microscopy
December 2, 2021/Cancer/Radiation Oncology
Study Identifies Prognostic Subgroups in Cutaneous Squamous Cell Carcinoma

Modification of traditional staging factors associated with survival in high-risk disease

Ad